2020-002729-27: Phase 3 study of pembrolizumab SC versus pembrolizumab IV, administered with platinum doublet chemotherapy, in 1L metastatic squamous or nonsquamous NSCLC |
|
|
| Ongoing | 3 | 450 | Europe | PEMBROLIZUMAB, MK-3475, Solution for injection in pre-filled syringe, Solution for infusion, KEYTRUDA (pembrolizumab, MK-3475) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer, Metastatic non-small cell lung cancer, Diseases [C] - Cancer [C04] | | | | |
KEYNOTE-A86, NCT04956692 / 2020-002729-27: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) |
|
|
| Active, not recruiting | 3 | 531 | Europe, Japan, US, RoW | Pembrolizumab SC, Pembrolizumab IV, MK-3475, KEYTRUDA®, SCH 900475, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Nab-Paclitaxel, Abraxane, Nanoparticle albumin-bound paclitaxel, Carboplatin, Paraplatin, Paraplatin NovaPlus, Cisplatin, Platinol-AQ, Pemetrexed, LY231514, Alimta, Pemetrexed Disodium | Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | Non-Small Cell Lung Cancer | 04/23 | 10/26 | | |
